Company: BDRX
Filing Date: 2025-05-12
Form Type: 424B3
Source: 0001214659-25-007341
Chunk: 8

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-05-12
Form: 424B3
Chunk 8
---
 manufacturers.

Commercialization

Once proof-of-concept has
been established, we intend to seek to license our products to a partner who would complete the development, and subsequently market and
sale, of the product in an agreed upon licensed territory. In addition to reimbursement of development costs, the partner would be expected
to make milestone payments based on sales targets and royalty payments.

| 5 |

Pipeline and Platform Technologies

We
are actively pursuing the development of eRapa in FAP, tolimidone in T1D and MTX110 in three indications. Our development pipeline is
as follows:

Our Corporate Information

Our
principal executive offices are located at 1 Caspian Point, Caspian Way, Cardiff, CF10 4DQ, United Kingdom. The telephone number at our
principal executive office is +44 29 20480 180. Our corporate website is located at www.biodexapharma.com. Information contained on our
website is not part of, or incorporated in, this prospectus. Our authorized representative in the United States is Donald J. Puglisi of
Puglisi and Associates. Our agent for service in the United States is Donald J. Puglisi of Puglisi and Associates, located at 850 Library
Avenue, Suite 204, Newark, Delaware 19711. Our Depositary Shares are traded on the NASDAQ Capital Market under the symbol “BDRX.”

Implications of Being a Foreign Private Issuer

We are incorporated as a public
limited company in England and Wales, and we are deemed to be a “foreign private issuer” for the purposes of the reporting
rules under the Securities Exchange Act of 1934, as amended, or the Exchange Act. In our capacity as a foreign private issuer, we are
exempt from certain rules under the Exchange Act that would otherwise apply if we were a company incorporated in the United States, including:

| · | the requirement to file periodic reports and financial statements with the SEC as frequently or as promptly 
 as United States companies with securities registered under the Exchange Act;                               |

| · | the requirement to file financial statements in accordance with accounting principles generally accepted 
 in the United States, or U.S. GAAP;                                                                      |

| 6 |

| · | the proxy rules, which impose certain disclosure and procedural requirements for proxy solicitations; 
 and                                                                                                   |

| · | the requirement to comply with Regulation FD, which imposes certain restrictions on the selective